Methotrexate-related lymphoproliferative disorders in the liver: Case presentation and mini-review

Figure 1 Serial computed tomography of liver tumors in a patient with methotrexate-associated lymphoproliferative disorder. Before (A) and after discontinuation of methotrexate at (B) 2 wk; (C) 1 mo; and (D) 2 mo, at which point all liver tumors had disappeared.

Figure 2 Histology of liver tumors in a patient with methotrexate-associated lymphoproliferative disorder. HE staining (A, × 10) shows significant proliferation of lymphocytes in the liver, seen as masses that, on immunohistochemical staining; are positive for CD3 (B, × 20); CD4 (C, × 40); CD8 (D, × 40); and CD79a (E, × 20) but negative for CD20 (F, × 20) and CD56 (G, × 40). Staining for Epstein-Barr virus-encoded RNA (H, × 20) was negative.